Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer

@inproceedings{Conibear2018StudyPF,
  title={Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer},
  author={John Conibear and Brendan Chia and Y. Leung Ngai and Andrew Tom Bates and Nicholas Counsell and Rushil Patel and David J Eaton and Corinne Faivre-Finn and J. Fenwick and M. Forster and Gerard G Hanna and Susan V. Harden and Philip Mayles and Syed S Moinuddin and David B. Landau},
  booktitle={BMJ open},
  year={2018}
}
INTRODUCTION Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS… CONTINUE READING